In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

BACKGROUND: Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ocio, Enrique M., Vilanova, David, Atadja, Peter, Maiso, Patricia, Crusoe, Edvan, Fernández-Lázaro, Diego, Garayoa, Mercedes, San-Segundo, Laura, Hernández-Iglesias, Teresa, de Álava, Enrique, Shao, Wenlin, Yao, Yung-Mae, Pandiella, Atanasio, San-Miguel, Jesús F.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2010
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864386/
https://ncbi.nlm.nih.gov/pubmed/19951978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.015495
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados